These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17333568)

  • 41. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth.
    Grange JM; Krone B; Stanford JL
    Eur J Cancer; 2009 Sep; 45(13):2266-73. PubMed ID: 19497734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Melanoma: early detection saves lives.
    Heinan ML;
    JAAPA; 2009 May; 22(5):18, 21. PubMed ID: 19469386
    [No Abstract]   [Full Text] [Related]  

  • 43. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
    Gajewski TF
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Melanoma vaccines: in search of a clinical paradigm.
    Storkus WJ
    Melanoma Res; 2007 Jun; 17(3):137-8. PubMed ID: 17505258
    [No Abstract]   [Full Text] [Related]  

  • 45. [Prognosis assessment in malignant melanoma: relevance for decisions regarding adjuvant therapies and after care].
    Sterry W
    J Dtsch Dermatol Ges; 2008 Mar; 6(3):171. PubMed ID: 18315620
    [No Abstract]   [Full Text] [Related]  

  • 46. Getting under the skin with melanoma vaccines.
    Bonn D
    Lancet; 1996 Aug; 348(9024):396. PubMed ID: 8709743
    [No Abstract]   [Full Text] [Related]  

  • 47. Skin diseases with high public health impact. Melanoma.
    Murphy GM
    Eur J Dermatol; 2007; 17(6):559-62. PubMed ID: 17951156
    [No Abstract]   [Full Text] [Related]  

  • 48. Vitiligo-like primary melanoma.
    Lugo-Somolinos A; Sánchez JL; Garcia ME
    Am J Dermatopathol; 2008 Oct; 30(5):451-4. PubMed ID: 18806487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune and gene therapy for melanoma, and the immunobiology of melanoma.
    Smith KJ; Skelton H
    Int J Dermatol; 1999 Jul; 38(7):490-508. PubMed ID: 10440277
    [No Abstract]   [Full Text] [Related]  

  • 50. [High follow-up, low follow-up, no follow-up?].
    Voit C
    J Dtsch Dermatol Ges; 2007 Oct; 5(10):869-70. PubMed ID: 17910668
    [No Abstract]   [Full Text] [Related]  

  • 51. [Working group of the Dermatologic Oncology].
    Hauschild A; Schadendorf D
    J Dtsch Dermatol Ges; 2009 Aug; 7(8):726-7. PubMed ID: 19708958
    [No Abstract]   [Full Text] [Related]  

  • 52. Skin layer-specific Melan-A expression during progression of human cutaneous melanoma: implications for diagnostic applications of the marker.
    Sztramska A; Dymerska D; Chwirot BW
    Melanoma Res; 2008 Aug; 18(4):259-67. PubMed ID: 18626310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Dermal melanoma, now-day condition].
    Seriakov AP; Korzhikov AV; Lamotkin IA
    Voen Med Zh; 2007 Dec; 328(12):15-25, 96. PubMed ID: 18314783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Follow-up of melanoma patients: the need for evidence-based protocols.
    Francken AB; Hoekstra HJ
    Ann Surg Oncol; 2009 Apr; 16(4):804-5. PubMed ID: 19189190
    [No Abstract]   [Full Text] [Related]  

  • 55. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
    Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
    Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dendritic cells and melanoma therapy.
    Goding C
    Pigment Cell Melanoma Res; 2009 Feb; 22(1):1. PubMed ID: 19154233
    [No Abstract]   [Full Text] [Related]  

  • 57. [Re: innovative therapeutic approaches in melanoma].
    Vereecken P; Awada A; Devriendt D; Laporte M; Heenen M; Salès F; Cappello M
    Rev Med Brux; 2004 Dec; 25(6):S 542. PubMed ID: 15688894
    [No Abstract]   [Full Text] [Related]  

  • 58. Therapeutic vaccines in solid tumours: can they be harmful?
    Eggermont AM
    Eur J Cancer; 2009 Aug; 45(12):2087-90. PubMed ID: 19477117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Important first chance.
    Avery JK
    J Ark Med Soc; 2007 May; 103(11):269. PubMed ID: 17539456
    [No Abstract]   [Full Text] [Related]  

  • 60. Melanoma: an under-recognized cancer threat.
    Esper P
    Oncology (Williston Park); 2009 Jul; 23(8 Suppl):22. PubMed ID: 19860038
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.